Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report
{{output}}
Background: Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung d... ...
